Skip to main
DBD

DBD Stock Forecast & Price Target

DBD Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Diebold Nixdorf Inc has demonstrated robust growth indicators, with a 17% year-over-year increase in order entry for 2025, driven by strong demand across its Banking and Retail segments. The Banking segment reported product revenues of $381.0 million, reflecting a 20% increase year-over-year, while total Banking revenues rose to $798 million, marking a 16% quarter-over-quarter and 11% year-over-year increase. Furthermore, the company achieved free cash flow of $196 million in CQ4, growing 5.4% year-over-year, and marking its first year of positive free cash flow in all four quarters, indicating a strong financial foundation and sustainability heading into 2026 and beyond.

Bears say

The financial outlook for Diebold Nixdorf Inc. appears negative due to expected sequential declines in backlog and quarterly results, consistent with seasonal trends that impact revenue recognition. While the company has targeted significant cash flow generation of over $800M from 2025 to 2027, the current market environment poses risks related to tariff costs, supply chain disruptions, and volatility in order trends within the banking segment, which represents the bulk of its revenue. Additionally, concerns about liquidity and ownership concentration, given the low average daily trading volume, may further hinder investor confidence and stock performance.

DBD has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Diebold Nixdorf Inc (DBD) Forecast

Analysts have given DBD a Buy based on their latest research and market trends.

According to 2 analysts, DBD has a Buy consensus rating as of Apr 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Diebold Nixdorf Inc (DBD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.